Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Trial Investigating the Pharmacokinetic (Mode of Action in the Body) and Safety Profiles of NN1250 (Insulin Degludec) in Subjects With Various Degrees of Impaired Liver Function and in Subjects With Normal Liver Function
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 12
- Registration Number
- NCT00976326
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1006
- Registration Number
- NCT00972283
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Mersin, Turkey
Comparison of Two NN1250 Formulations in Healthy Volunteers
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 27
- Registration Number
- NCT00966368
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Chula Vista, California, United States
A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 27
- Registration Number
- NCT00964418
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- Drug: placebo
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 18
- Registration Number
- NCT00964964
A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 54
- Registration Number
- NCT00961324
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Observational Prospective Study on Patients Treated With Norditropin®
Completed
- Conditions
- Growth Hormone DisorderChronic Renal InsufficiencyFoetal Growth ProblemAdult Growth Hormone DeficiencySmall for Gestational AgeNoonan SyndromeGrowth Hormone Deficiency in ChildrenGenetic DisorderTurner SyndromeChronic Kidney Disease
- Interventions
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 21249
- Registration Number
- NCT00960128
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom
Comparison of Repaglinide and Metformin Combination Tablet Versus Repaglinide and Metformin as Separate Tablets in Healthy Volunteers
Phase 1
Completed
- Conditions
- HealthyDiabetes
- Interventions
- First Posted Date
- 2009-08-14
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT00959101
Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B
Phase 1
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia B
- Interventions
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 18
- Registration Number
- NCT00956345
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Oxford, United Kingdom
A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia AHaemophilia BHealthy
- Interventions
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 38
- Registration Number
- NCT00951873
© Copyright 2025. All Rights Reserved by MedPath